In September 2025, BioWorld recorded 230 clinical trial updates spanning phases I through III, up sharply from 95 in August, ...

Hanmi Pharmaceutical Co. Ltd. announced Oct. 27 that its glucagon-like peptide-1 receptor agonist, efpeglenatide (HM-11260C), met the co-primary endpoints in a phase III study of obese adults without ...

Penumbra Inc.’s 'resoundingly positive' results from its STORM-PE trial could see current guidelines for anticoagulant use in ...

Researchers at Monash University in Melbourne, Australia, have uncovered the hidden code governing how genetic mutations affect RNA splicing and result in disease. The researchers were able to ...

The $12.5 billion acquisition of Avidity Biosciences Inc. by Novartis AG strengthens the company’s neuroscience pipeline and marks the second biggest deal that’s been announced this year. San ...

U.K. biotech companies raised 46% less in the third quarter (Q3) of 2025 than in the previous quarter, at £187 million ...

Trials are being conducted at three pediatric emergency departments in England of the Memed BV rapid blood test, designed to ...

Doctors and device makers are habituated to the notion that more devices equal better outcomes, but one presenter at this ...

Although Argenica Therapeutics Ltd.’s stroke drug, ARG-007, saw mixed results in top-line phase II data, new data in ...

Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has described polypeptides acting as glucagon-like peptide 1 receptor (GLP-1R), glucagon receptor (GCGR) and gastric inhibitory polypeptide receptor ...

Resolute Science Inc.’s RS-5 has been awarded orphan drug designation by the FDA for the treatment of soft tissue sarcomas.

Amphista Therapeutics Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an F-Box only protein 22 (FBXO22)-binding moiety coupled to a transcriptional enhancer factor TEF ...